Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.
From Torrent Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. (Page 4)
- Brazil branded generics market grew 10% YoY; Torrent grew 13% with healthy volume growth and mid-single digit pricing increase; expects 5-6 new product launches in Brazil. (Pages 3, 14)
- U.S. business saw 12% growth in constant currency; targeting a directional increase in sales with at least 5-7 launches per year and aims to cross $200 million annual sales by FY27. (Pages 3, 9)
- Germany facing supply disruptions, growth affected; alternative supplier efforts ongoing but will take 3-4 quarters. (Page 4)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Torrent Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- There is no explicit mention of current or future capex/capital investment or strategic investment in the provided pages (up to page 15).
- However, there is mention of ongoing work to address supply disruptions in Germany by moving some products to Torrent's own facilities, which implies some capital investment in manufacturing (Page 4).
- For GLP-1 injectable products, Torrent does not have fill and finish capacity and will partner for manufacturing and launch, indicating a strategic partnership approach rather than immediate capex (Page 4).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Torrent Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.2K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Torrent Pharmaceuticals Ltd's management said in earlier quarters
- Q4 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Torrent Pharmaceuticals Ltd Q3 FY26 results?
India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.
What is Torrent Pharmaceuticals Ltd share price analysis?
Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 82.4 with a market cap of ₹183,832 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharmaceuticals Ltd planning capital expenditure?
There is no explicit mention of current or future capex/capital investment or strategic investment in the provided pages (up to page 15).
Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.